Frank V. Leopardi

551 total citations
11 papers, 440 citations indexed

About

Frank V. Leopardi is a scholar working on Transplantation, Immunology and Surgery. According to data from OpenAlex, Frank V. Leopardi has authored 11 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Transplantation, 6 papers in Immunology and 5 papers in Surgery. Recurrent topics in Frank V. Leopardi's work include Renal Transplantation Outcomes and Treatments (7 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (3 papers). Frank V. Leopardi is often cited by papers focused on Renal Transplantation Outcomes and Treatments (7 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (3 papers). Frank V. Leopardi collaborates with scholars based in United States and Austria. Frank V. Leopardi's co-authors include Allan D. Kirk, Mingqing Song, Tim Weaver, Alexandra P. Turner, Maria C. Russell, Christian P. Larsen, Avinash Kumar Ágarwal, Robert L. Kampen, Linda Stempora and Ali H. Charafeddine and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Kidney International.

In The Last Decade

Frank V. Leopardi

11 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frank V. Leopardi United States 8 258 231 188 54 45 11 440
Joel Trambley United States 5 452 1.8× 132 0.6× 137 0.7× 45 0.8× 51 1.1× 7 582
Janghoon Yoon United States 9 168 0.7× 220 1.0× 155 0.8× 44 0.8× 37 0.8× 22 332
Karoline Edtinger Germany 11 193 0.7× 122 0.5× 121 0.6× 74 1.4× 33 0.7× 13 376
Dora Ninova United States 8 97 0.4× 198 0.9× 187 1.0× 22 0.4× 22 0.5× 12 345
F. Leopardi United States 14 273 1.1× 244 1.1× 427 2.3× 44 0.8× 178 4.0× 25 712
Jonathan M. Fishbein United States 11 194 0.8× 137 0.6× 203 1.1× 13 0.2× 50 1.1× 22 410
Khodor I. Abou‐Daya United States 10 224 0.9× 86 0.4× 81 0.4× 38 0.7× 15 0.3× 13 341
Kerry Crisalli United States 6 119 0.5× 199 0.9× 151 0.8× 40 0.7× 11 0.2× 9 337
Jan Schmidtko Germany 9 142 0.6× 39 0.2× 158 0.8× 33 0.6× 95 2.1× 22 371
Jaclyn R. Espinosa United States 7 248 1.0× 123 0.5× 57 0.3× 64 1.2× 27 0.6× 12 363

Countries citing papers authored by Frank V. Leopardi

Since Specialization
Citations

This map shows the geographic impact of Frank V. Leopardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank V. Leopardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank V. Leopardi more than expected).

Fields of papers citing papers by Frank V. Leopardi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank V. Leopardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank V. Leopardi. The network helps show where Frank V. Leopardi may publish in the future.

Co-authorship network of co-authors of Frank V. Leopardi

This figure shows the co-authorship network connecting the top 25 collaborators of Frank V. Leopardi. A scholar is included among the top collaborators of Frank V. Leopardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank V. Leopardi. Frank V. Leopardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Gao, Qimeng, Robert D. Davis, Zachary W. Fitch, et al.. (2021). Anti‐thymoglobulin induction improves neonatal porcine xenoislet engraftment and survival. Xenotransplantation. 28(6). 9 indexed citations
2.
Schroder, Paul M., Robin Schmitz, Zachary W. Fitch, et al.. (2020). Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. Kidney International. 99(1). 161–172. 36 indexed citations
3.
Schroder, Paul M., Robin Schmitz, Zachary W. Fitch, et al.. (2020). CARFILZOMIB AND LULIZUMAB-BASED DESENSITIZATION PROLONGS ALLOGRAFT SURVIVAL IN SENSITIZED NON-HUMAN PRIMATES KIDNEY TRANSPLANTATION MODEL. Transplantation. 104(S3). S46–S46. 2 indexed citations
4.
Samy, Kannan P., Qimeng Gao, Robert P. Davis, et al.. (2019). The role of human CD46 in early xenoislet engraftment in a dual transplant model. Xenotransplantation. 26(6). e12540–e12540. 14 indexed citations
5.
Green, Jason, Jeffrey I. Everitt, Richard R. Glisson, et al.. (2019). Soft Tissue Anchoring Performance, Biomechanical Properties, and Tissue Reaction of a New Hernia Mesh Engineered to Address Hernia Occurrence and Recurrence. Journal of Medical Devices. 13(4). 450021–450029. 6 indexed citations
6.
Burghuber, Christopher, Miriam Manook, Brian Ezekian, et al.. (2018). Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. American Journal of Transplantation. 19(3). 724–736. 61 indexed citations
7.
Badell, I.R., Maria C. Russell, Peter Thompson, et al.. (2010). LFA-1–specific therapy prolongs allograft survival in rhesus macaques. Journal of Clinical Investigation. 120(12). 4520–4531. 83 indexed citations
8.
Weaver, Tim, Ali H. Charafeddine, Avinash Kumar Ágarwal, et al.. (2009). Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nature Medicine. 15(7). 746–749. 144 indexed citations
9.
10.
Dhanireddy, Kiran, Bruno David, Xiaojie Zhang, et al.. (2006). Alefacept (LFA3-Ig), portal venous donor specific transfusion (PVDST), and sirolimus prolong renal allograft survival in non-human primates. Journal of the American College of Surgeons. 203(3). S92–S92. 2 indexed citations
11.
Xu, He, Kiran Dhanireddy, Jonathan P. Pearl, et al.. (2005). IDEC-131 (Anti-CD154), Sirolimus and Donor-Specific Transfusion Facilitate Operational Tolerance in Non-Human Primates. American Journal of Transplantation. 5(5). 1032–1041. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joel Trambley Breakdown of academic impact, for papers by Janghoon Yoon Breakdown of academic impact, for papers by Karoline Edtinger Breakdown of academic impact, for papers by Dora Ninova Breakdown of academic impact, for papers by F. Leopardi Breakdown of academic impact, for papers by Jonathan M. Fishbein Breakdown of academic impact, for papers by Khodor I. Abou‐Daya Breakdown of academic impact, for papers by Kerry Crisalli Breakdown of academic impact, for papers by Jan Schmidtko Breakdown of academic impact, for papers by Jaclyn R. Espinosa
Rankless by CCL
2026